Latest News

Chainguard recently launched its Commercial Builds program to help software vendors and open source providers ship software with zero known vulnerabilities, naming GitLab as one of its initial partners. This partnership reinforces GitLab's role in secure-by-default DevSecOps workflows, potentially deepening its relevance for organizations prioritizing end-to-end software supply chain security. We’ll now examine how GitLab’s role in Chainguard Commercial Builds might influence its investment...

Wondering if CCL Industries at around $85.80 is offering fair value or a potential bargain? This article breaks down what the current price might be saying about the stock. The share price sits at $85.80 after a 0.2% move over the past week, a 0.6% decline over 30 days, and a 2.1% decline year to date, even as the 1 year return stands at 22.3% and the 3 and 5 year returns are 39.0% and 37.2% respectively. Recent coverage around CCL Industries has focused on its position as a packaging and...

Pilgrim's Pride (PPC) shares came into focus after fourth quarter results showed revenue growth, while earnings did not meet expectations, with Mexico profitability pressured by higher imports and softer commodity prices. See our latest analysis for Pilgrim's Pride. At a share price of $37.33, Pilgrim's Pride has a 1 day share price return of 1.61%, while the 30 day share price return of 13.83% and 1 year total shareholder return of 11.28% suggest recent momentum has cooled after strong multi...

On March 11, 2026, Viking Holdings took delivery of the Viking Eldir, a 190-guest Longship built at Meyer’s Neptun Werft in Germany to operate on Rhine, Main and Danube river itineraries such as Rhine Getaway and Grand European Tour. The addition of Viking Eldir strengthens Viking’s river network by increasing capacity on high-demand European routes and enhancing access to exclusive docking locations that underpin its long-term expansion plans. We’ll now examine how adding Viking Eldir to...

Share buyback completion and what it means for Sanwa Holdings Sanwa Holdings (TSE:5929) has just wrapped up its share repurchase program, buying 2,515,600 shares, or 1.19% of outstanding stock, for ¥9,999.66 million by March 16, 2026. See our latest analysis for Sanwa Holdings. The buyback comes at a time when Sanwa Holdings' share price return has eased. The 1-day share price return of 1.98% contrasts with a 90-day share price return decline of 6.99% and a 1-year total shareholder return...

Axon Enterprise stock reacts to upbeat outlook after strong Q4 Axon Enterprise (AXON) has been back in focus after Q4 2025 results came in ahead of expectations, supported by demand for premium software, TASER 10, Axon Body 4, and counter-drone products. The company paired that performance with higher 2026 revenue guidance and a long term 2028 revenue target of US$6b. These moves have reinforced already optimistic analyst views and pushed the shares sharply higher. See our latest analysis for...

Dorchester Minerals, L.P. and Dorchester Minerals Operating LP have settled ordinary course litigation over certain Midland County, Texas leasehold interests, receiving US$15,500,000 that will be reflected in the April 2026 Net Profits Interest payment. This one-time legal settlement injects an immediate cash inflow tied directly to assets underpinning Dorchester Minerals’ Net Profits Interest structure. We will now consider how this US$15,500,000 settlement shapes Dorchester Minerals’...

Why Coloplast’s CEO transition is in focus Coloplast (CPSE:COLO B) is back on investors’ radar after the board appointed Gavin Wood as President and CEO, effective 1 May 2026, following a year under interim chief Lars Rasmussen. Wood arrives from senior roles at Johnson & Johnson MedTech EMEA and previous leadership positions at Mölnlycke and Ethicon, raising questions about how his background could shape Coloplast’s future direction and its healthcare portfolio. See our latest analysis for...

Pulse Biosciences, Inc. recently shifted its capital allocation to prioritize and accelerate development of its nPulse Cardiac Catheter Ablation System after reporting strong European feasibility data in atrial fibrillation patients, while scaling back near-term spending in cardiac surgery and soft-tissue ablation programs. The move effectively concentrates the company’s resources on a single electrophysiology platform that early data suggest may offer an unusual mix of speed, safety and...

Immatics N.V. reported full-year 2025 results showing a net loss of €196.45 million, reversing from net income of €15.22 million in 2024, alongside a shift from earnings per share to a loss per share. At the same time, the company highlighted strong enrollment in its Phase 3 SUPRAME trial for lead therapy anzu-cel (IMA203), underlining how its expanding oncology pipeline is increasingly driving the business story despite recent losses. Against this backdrop, we will examine how progress in...

What Equifax’s recent share performance tells you Equifax (EFX) has seen its share price under pressure, with a 12.5% decline year to date and a 19.8% total return decline over the past year, prompting closer attention from investors. Over the past month, the stock shows a 2.8% decline, widening to a 14.1% total return decline over the past 3 months. These moves contrast with longer term returns, where the past 5 years show a 10.7% total return gain. See our latest analysis for Equifax. At a...

In recent weeks, Permian Resources increased its quarterly dividend and saw a sharp reduction in short interest, while analysts highlighted the company’s free cash flow potential amid ongoing Middle East tensions. Together, these developments point to growing confidence in Permian Resources’ ability to generate cash and return capital, even as geopolitical risks keep energy markets on edge. Next, we’ll examine how the higher dividend and shifting short interest influence Permian Resources’...

Abaxx Technologies (NEOE:ABXX) has drawn fresh attention after announcing it will showcase MarketOS at the FIA Global Cleared Markets Conference, where it will highlight a new approach to post-trade collateral movement using its ID++ identity protocol. See our latest analysis for Abaxx Technologies. Despite the MarketOS announcement and FIA conference spotlight, Abaxx’s share price return has been weak in the short term, with a 30 day move of 11.78% and a year to date decline of 22.88%...

JCDecaux (ENXTPA:DEC) has just released its FY 2025 numbers, with second half revenue of €1.94b and basic EPS of €0.88, while trailing 12 month EPS stands at €1.23 on revenue of €3.67b. This gives a clear view of its recent earnings power. Over the past few reporting halves, the company has seen revenue in a tight band between €1.73b and €1.97b and basic EPS ranging from €0.35 to €0.88. This frames the current results within a fairly consistent earnings profile. With a current net profit...

Astellas Pharma and the HOVON Foundation reported that the Phase 3 HOVON 156/AMLSG 28-18/PASHA trial of XOSPATA (gilteritinib) in newly diagnosed FLT3-mutated acute myeloid leukemia did not meet its primary endpoint of overall survival at the primary analysis, with overall survival and safety broadly similar to midostaurin-based treatment. Although Astellas expects only a minor impact on financial results for the fiscal year ending March 31, 2026, the outcome underscores how clinical...

DENTSPLY SIRONA (XRAY) shares are in focus after the company and Siemens Healthineers received FDA clearance for MAGNETOM Free.Max Dental Edition, the first dental dedicated MRI system designed for non ionizing imaging across multiple dental specialties. See our latest analysis for DENTSPLY SIRONA. The FDA clearance comes as DENTSPLY SIRONA’s 1 day share price return of 4.18% contrasts with a weaker 30 day share price return of a 5.64% decline and a 1 year total shareholder return of an...

On March 12, 2026, Calumet, Inc. entered into a Tenth Amendment to its Third Amended and Restated Credit Agreement, allowing the company to issue additional notes and incur more indebtedness under its long-standing facility with Bank of America as administrative agent. This added flexibility to raise debt financing could influence how investors assess Calumet’s balance sheet resilience and its capacity to fund future projects or refinancing efforts. Next, we’ll examine how this expanded...

General Mills (NYSE:GIS) has agreed to sell its Brazil business, including local brands Yoki and Kitano, as part of a portfolio reshaping move. The company is also relaunching its La Tiara taco shells and seasonings nationwide in the U.S., expanding distribution beyond prior regional availability. These actions focus the portfolio on areas where General Mills reports stronger alignment with its priorities and margin goals. General Mills operates across packaged foods categories, with brands...

Astera Labs recently presented at the NVIDIA GTC AI Conference 2026 in San Jose, highlighting its connectivity solutions for AI and cloud infrastructure, while analysts updated research following a newly announced US$6.50 billion warrant agreement with Amazon that ties future equity to long-term collaboration. This combination of a high-profile ecosystem presence and a large warrant-linked partnership with Amazon underscores how central Astera Labs has become to addressing AI server and...

In recent days, Nutrien Ltd. received upgrades from Wells Fargo and Jefferies, with both firms highlighting the company’s prospects amid tightening global fertilizer supply following disruptions around the Strait of Hormuz. These reassessments underline how Nutrien’s scale as the world’s largest fertilizer producer by capacity can make it a key supplier when trade routes are constrained. We’ll now examine how this analyst confidence, set against supply disruptions in fertilizer markets, may...

In March 2026, Goldman Sachs issued a flurry of new fixed‑income instruments across a wide range of maturities, while long‑time director Lakshmi Mittal prepared to retire at the 2026 annual meeting under the board’s age-based policy. At the same time, the firm’s commodity and macro research came into sharp focus as its oil shock analysis and recession odds framed investor debate on the Middle East conflict’s global impact. We’ll examine how Goldman’s high-profile oil shock research and macro...

Recent share performance context for Everest Group Everest Group (EG) has drawn investor attention after recent share price moves, with the stock posting a 0.6% gain over the past day but declines over the past week and month. See our latest analysis for Everest Group. At a share price of US$322.50, Everest Group’s recent 1 day share price return contrasts with its weaker year to date share price return of 3.6% and a 1 year total shareholder return decline of 8.1%, suggesting momentum has...

Springer Nature KGaA (XTRA:SPG) has reported solid headline numbers for FY 2025, with first half revenue of €969.9 million and basic EPS of €0.65. Trailing 12 month revenue stands at about €1.9 billion and EPS at €0.81, against a current share price of €16.98. The company has seen revenue increase from €940.5 million to €969.9 million between the first halves of 2024 and 2025, with basic EPS over the same period rising from €0.17 to €0.65. This places expanding net profit margins at the...

Stoke Therapeutics (STOK) has reported FY 2025 results that feature a wide range of quarterly outcomes. Q1 revenue was US$158.6 million with EPS of US$1.95, followed by Q2 revenue of US$13.8 million and an EPS loss of US$0.40, and Q3 revenue of US$10.6 million with an EPS loss of US$0.65. Over recent periods the company has seen revenue move between US$4.8 million and US$158.6 million per quarter, while EPS has shifted from a US$2.07 loss in FY 2024 to a US$1.95 profit and then back into...